Kvíz spojený s průvodcem · Střední úroveň

EMA and AI in Medicines Regulation Quiz

Tests EMA reflection-paper status, lifecycle scope, function-specific evidence, oversight, and distinction from product authorization.

Související vodicí cestyEma And AI In Medicines Regulation
Otázka 1 z 8

Which statement describes the status of EMA’s AI reflection paper?

Náhled každé otázky8 otázky

Odpovědi a vysvětlení se zobrazují, jak budete v kvízu.

  1. Which statement describes the status of EMA’s AI reflection paper?
    • It describes regulatory considerations but is not an AI product authorization
    • It grants automatic approval to AI tools
    • It replaces medicines legislation
    • It is a standalone CE certificate
  2. Which stages of medicines work may involve AI?
    • Only clinical diagnosis
    • Only hospital billing
    • Research, development, manufacturing, and medicine use
    • Only marketing
  3. What should developers define before evaluating an AI function?
    • The total number of data records
    • Its intended purpose, context, users, and consequences of error
    • Only its neural-network architecture
    • The vendor’s product slogan
  4. Why does human oversight matter for higher-impact uses?
    • It guarantees that the model is accurate
    • It replaces data validation
    • It makes change control unnecessary
    • Qualified review and escalation help manage uncertain or erroneous outputs
  5. Which controls should accompany changes to an AI model over time?
    • Versioning, change management, monitoring, and traceability
    • Nothing if the model remains AI
    • A new medicine approval for every typo
    • A single performance report from development
  6. Does the reflection paper create one universal AI approval pathway?
    • Yes, one pathway applies to every algorithm
    • Yes, if the tool is used for medicine
    • No AI use can be regulated
    • No; existing requirements depend on the function and product
  7. How should clinical trial AI be documented?
    • No details if the trial is blinded
    • With data provenance, protocol alignment, validation, and limitations
    • Only a vendor name
    • Only the output score
  8. What should a sponsor consult before deploying AI in EU medicines work?
    • A general AI product blog
    • A prior model card regardless of use
    • Current EMA and applicable EU guidance and legislation
    • Only the reflection paper in isolation